Zobrazeno 1 - 10
of 252
pro vyhledávání: '"Kazumi, Nishino"'
Autor:
Hirotsugu Kenmotsu, MD, PhD, Kazuko Sakai, PhD, Keita Mori, PhD, Terufumi Kato, MD, Shunichi Sugawara, MD, PhD, Keisuke Kirita, MD, PhD, Yasuto Yoneshima, MD, PhD, Koichi Azuma, MD, PhD, Kazumi Nishino, MD, PhD, Shunsuke Teraoka, MD, Ryo Koyama, MD, PhD, Ken Masuda, MD, PhD, Hidetoshi Hayashi, MD, PhD, Ryo Toyozawa, MD, PhD, Satoru Miura, MD, PhD, Yuki Sato, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuto Nishio, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100716- (2024)
Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive EGFR mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus beva
Externí odkaz:
https://doaj.org/article/4c7148e01a2e473a80756678fc890a30
Autor:
Takako Inoue, Kei Kunimasa, Motohiro Tamiya, Takahisa Kawamura, Toshiyuki Minami, Kazumi Nishino
Publikováno v:
Thoracic Cancer, Vol 15, Iss 11, Pp 929-933 (2024)
Abstract We present a patient with lung adenocarcinoma showing high PD‐L1 expression and BRAF V600E mutation, who achieved a remarkable long‐term response to the combination therapy of dabrafenib and trametinib (DT treatment) after disease progre
Externí odkaz:
https://doaj.org/article/8d66f6c5b4744281b900c0ad4f7f6b80
Autor:
Tasuku Nakabori, Kei Kunimasa, Masaki Kawabata, Sena Higashi, Kaori Mukai, Takahisa Kawamura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Kazuyoshi Ohkawa
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Aim Atezolizumab and bevacizumab (Atezo/Bev) combination immunotherapy regimens and direct oral anticoagulants (DOACs) are both associated with bleeding. Therefore, combining Atezo/Bev regimens with DOACs may exacerbate the bleeding risk. Th
Externí odkaz:
https://doaj.org/article/6133491ea5814b7aa992d3c06c4daae2
Autor:
Kei Kunimasa, Shingo Matsumoto, Keiichiro Honma, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Satoshi Tanada, Akito Miyazaki, Ryu Kanzaki, Tomohiro Maniwa, Jiro Okami, Yuji Matsumoto, Koichi Goto, Kazumi Nishino
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background It is essential to collect a sufficient amount of tumor tissue for successful next-generation sequencing (NGS) analysis. In this study, we investigated the clinical risk factors for avoiding re-biopsy for NGS analysis (re-genome b
Externí odkaz:
https://doaj.org/article/8068f32a5bac4be8b8a6cb9cbd42ca65
Autor:
Kei Kunimasa, Yosuke Hirotsu, Kenji Amemiya, Keiichiro Honma, Harumi Nakamura, Kazumi Nishino, Masao Omata
Publikováno v:
Thoracic Cancer, Vol 14, Iss 22, Pp 2210-2215 (2023)
Abstract In this study, we investigated the association between PD‐L1 expression in tumor cells and underlying genetic mutations, which was analyzed in detail using laser microdissection and next‐generation sequencing analysis. To investigate whe
Externí odkaz:
https://doaj.org/article/394cbfdb28f54f2783e5a8a89886f7da
Autor:
Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100624- (2024)
Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients wit
Externí odkaz:
https://doaj.org/article/5159d19b07b0438c8a46366db7862e0c
Autor:
Saki Tanaka, Motohiro Tamiya, Satoshi Nishiuma, Sayaka Nakamura, Keisuke Nozaki, Naoko Watanabe, Chisae Itoh, Yukio Kadokawa, Kenji Takeda, Kozo Takahashi, Akito Miyazaki, Takahisa Kawamura, Kei Kunimasa, Takako Inoue, Kazumi Nishino, Mari Takagi
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100836- (2024)
Background: The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however some patients withdraw or reduce the dosage d
Externí odkaz:
https://doaj.org/article/4b349845690a4c3a9c26c010b0b54cf5
Autor:
Yuhei Kinehara, MD, PhD, Takayuki Shiroyama, MD, PhD, Akihiro Tamiya, MD, Motohiro Tamiya, MD, Seigo Minami, MD, PhD, Masaki Kanazu, MD, Osamu Morimura, MD, PhD, Toshie Niki, MD, PhD, Satoshi Tetsumoto, MD, PhD, Yoshihiko Taniguchi, MD, Tomoki Kuge, MD, Kazumi Nishino, MD, PhD, Izumi Nagatomo, MD, PhD, Atsushi Kumanogoh, MD, PhD, Isao Tachibana, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100586- (2023)
Introduction: Durvalumab consolidation therapy is the standard of care after concurrent chemoradiotherapy (CRT) for stage III NSCLC. Immune-related pneumonitis during durvalumab treatment is potentially fatal; however, information is lacking regardin
Externí odkaz:
https://doaj.org/article/c22883f5a74346ae94c511208d4a9489
Autor:
Kei Kunimasa, Takako Inoue, Yugo Kai, Ryu Kanzaki, Sachi Kawagishi, Ken‐ichi Yoshida, Keiichiro Honma, Motohiro Tamiya, Takahisa Kawamura, Kazumi Nishino
Publikováno v:
Thoracic Cancer, Vol 14, Iss 1, Pp 85-88 (2023)
Abstract Rapid and reliable identification of targetable driver mutations in patients with advanced stage lung cancer is essential. Adequate amount of tumor tissue biopsies (i.e., genomic biopsies) are required to successfully analyze the gene panel.
Externí odkaz:
https://doaj.org/article/972f9ed6b072498085c902e50ee20f7c
Autor:
Kei Kunimasa, Naotoshi Sugimoto, Takahisa Kawamura, Tomoyuki Yamasaki, Keiichiro Honma, Shigenori Nagata, Yoji Kukita, Fumie Fujisawa, Tazuko Inoue, Yuko Yamaguchi, Mitsuko Kitasaka, Toru Wakamatsu, Takuo Yamai, Sachiko Yamamoto, Takuji Hayashi, Takako Inoue, Motohiro Tamiya, Fumio Imamura, Kazuo Nishimura, Kazumi Nishino
Publikováno v:
Thoracic Cancer, Vol 13, Iss 21, Pp 2970-2977 (2022)
Abstract Background The usefulness of comprehensive genomic profiling (CGP) panels for thoracic malignancies after completion of the standard treatment is unclear. Methods The results of CGP panels for malignant thoracic diseases performed at our hos
Externí odkaz:
https://doaj.org/article/5cced9d17ae34c29aad0192b84e309a7